2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Clinical trial for Anle138b
The German biotech company, MODAG, announced that their first drug candidate for neurodegenerative conditions has started phase I safety testing in humans. The drug, Anle138b, is being developed for Parkinson’s and it has previously shown to rescue neurons in pre-clinical models of alpha synuclein-associated Parkinson’s….
Keeping Pace with LRRK2 and GCase
There are a number of genetic variations that can increase one’s risk of developing Parkinson’s. Two of the most common genetic variations or mutations occur in regions of human DNA known as the ‘LRRK2’ gene and the ‘GBA’ gene (a gene being a functional section…
GP2: global Parkinson’s genetics program
In almost every cell of a human body, genetic material or DNA is translated into proteins, referred to as genes. These genes provide the instructions for making and maintaining each individual. Small errors or mutations in certain genes, however, can result in increased risk of…
Genetic manipulators of Alpha Synuclein
In the brains of people with Parkinson’s, there is an accumulation of alpha synuclein protein. It clusters and aggregates together forming dense circular objects inside neurons called Lewy bodies. This build up of alpha synuclein is believed to play a role in the neurodegeneration associated…
Accelerating Medicines Partnership for Parkinson’s – AMP-PD
The US National Institute of Health (NIH) have recently announced the opening of a vast new data portal for Parkinson’s research. It is part of the Accelerating Medicines Partnership for Parkinson’s, or AMP-PD initiative. AMP-PD is a huge collaborative effort between the NIH and multiple…